Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome

Progress in Neurobiology

Volumn 91, Issue 1, 2010, Pages 1-22

  Contestabile, Andrea ^a   Benfenati, Fabio ^a   Gasparini, Laura ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Alzheimer's disease; Animal models; Cognitive disabilities; Developmental defects; Down syndrome; Neurodegeneration; Neurogenesis; Trisomy

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; BILOBALIDE; CHOLINESTERASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIZOCILPINE; DONEPEZIL; DUAL SPECIFICITY PHOSPHATASE; ESTRADIOL; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE EXCHANGE FACTOR; LITHIUM; MEMANTINE; MINOCYCLINE; NOOTROPIC AGENT; PENTETRAZOLE; PICROTOXIN; PIRACETAM; PLACEBO; RIVASTIGMINE; SGS 111; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NFAT; UBIDECARENONE; UNCLASSIFIED DRUG;

ADAPTIVE BEHAVIOR; ALZHEIMER DISEASE; AMNESIA; BIRTH DEFECT; CELL PROLIFERATION; CLINICAL TRIAL; COGNITIVE DEFECT; DEVELOPMENTAL STAGE; DOWN SYNDROME; GENE OVEREXPRESSION; GENETIC MODEL; HUMAN; HYPOPLASIA; INTELLECTUAL IMPAIRMENT; LANGUAGE ABILITY; LEARNING; MEMORY CONSOLIDATION; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOCIAL BEHAVIOR; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; TRISOMY; TRISOMY 21;

ANIMALS; BRAIN; CHROMOSOME MAPPING; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MENTAL RETARDATION; NEUROGENESIS; TRISOMY;

EID: 77952955690     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2010.01.003     Document Type: Review

References (332)

1. Akeson E.C., Lambert J.P., Narayanswami S., Gardiner K., Bechtel L.J., Davisson M.T. Ts65Dn-localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet. 2001, 93:270-276.
2. Alexander G.E., Saunders A.M., Szczepanik J., Strassburger T.L., Pietrini P., Dani A., Furey M.L., Mentis M.J., Roses A.D., Rapoport S.L., Schapiro M.B. Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Neuroreport 1997, 8:1835-1840.
3. Antonarakis E.S., Epstein C.J. The challeng of Down syndrome. Trends Mol. Med. 2006, 12:473-479.
4. Antonarakis S.E., Lyle R., Chrast R., Scott H.S. Differential gene expression studies to explore the molecular pathophysiology of Down syndrome. Brain Res. Brain Res. Rev. 2001, 36:265-274.
5. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and Down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004, 5:725-738.
6. Arron J.R., Winslow M.M., Polleri A., Chang C.P., Wu H., Gao X., Neilson J.R., Chen L., Heit J.J., Kim S.K., Yamasaki N., Miyakawa T., Francke U., Graef I.A., Crabtree G.R. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
7. Aylward E.H., Habbak R., Warren A.C., Pulsifer M.B., Barta P.E., Jerram M., Pearlson G.D. Cerebellar volume in adults with Down syndrome. Arch. Neurol. 1997, 54:209-212.
8. Aylward E.H., Li Q., Honeycutt N.A., Warren A.C., Pulsifer M.B., Barta P.E., Chan M.D., Smith P.D., Jerram M., Pearlson G.D. MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Am. J. Psychiatry 1999, 156:564-568.
9. Bahn S., Mimmack M., Ryan M., Caldwell M.A., Jauniaux E., Starkey M., Svendsen C.N. Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 2002, 359:310-315.
10. Ball M.J., Nuttall K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down syndrome: quantitative comparison with Alzheimer dementia. Ann. Neurol. 1980, 7:462-465.
11. Ball S.L., Holland A.J., Hon J., Huppert F., Treppner P., Watson P.C. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study. Int. J. Geriatr. Psychiatry 2006, 21:661-673.
12. Ball S.L., Holland A.J., Treppner P., Watson P.C., Huppert F.A. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Brit. J. Clin. Psychol. 2008, 47:1-29.
13. Bambrick L.L., Krueger B.K. Neuronal apoptosis in mouse trisomy 16: mediation by caspases. J. Neurochem. 1999, 72:1769-1772.
14. Bambrick L.L., Yarowsky P.J., Krueger B.K. Altered astrocyte calcium homeostasis and proliferation in theTs65Dn mouse, a model of Down syndrome. J. Neurosci. Res. 2003, 73:89-94.
15. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
16. Baxter L.L., Moran T.H., Richtsmeier J.T., Troncoso J., Reeves R.H. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum. Mol. Genet. 2000, 9:195-202.
17. Becker L.E., Armstrong D.L., Chan F. Dendritic atrophy in children with Down's syndrome. Ann. Neurol. 1986, 20:520-526.
18. Behar T.N., Colton C.A. Redox regulation of neuronal migration in a Down syndrome model. Free Radic. Biol. Med. 2003, 35:566-575.
19. Belichenko P.N., Belichenko P.V., Kleschevnikov A.M., Salehi A., Reeves R.H., Mobley W.C. The " Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 2009, 29:5938-5948.
20. Belichenko P.V., Kleschevnikov A.M., Masliah E., Wu C., Takimoto-Kimura R., Salehi A., Mobley W.C. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2009, 512:453-466.
21. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 2007, 504:329-345.
22. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., Mobley W.C. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2004, 480:281-298.
23. Benavides-Piccione R., Ballesteros-Yanez I., de Lagran M.M., Elston G., Estivill X., Fillat C., Defelipe J., Dierssen M. On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog. Neurobiol. 2004, 74:111-126.
24. Benavides-Piccione R., Dierssen M., Ballesteros-Yanez I., Martinez de Lagran M., Arbones M.L., Fotaki V., DeFelipe J., Elston G.N. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol. Dis. 2005, 20:115-122.
25. Benfenati F. Synaptic plasticity and the neurobiology of learning and memory. Acta Biomed. 2007, 78:58-66.
26. Bennett M.R., Gibson W.G., Robinson J. Dynamics of the CA3 pyramidal neuron autoassociative memory network in the hippocampus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1994, 343:167-187.
27. Best T.K., Siarey R.J., Galdzicki Z. Abnormal synaptic properties in Down syndrome: lessons from mouse models. Cell. Sci. Rev. 2006.
28. Bianchi P., Ciani E., Contestabile A., Guidi S., Bartesaghi R. Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol. 2009, 10.1111/j.1750-3639.2008.00246.x.
29. Bimonte-Nelson H.A., Hunter C.L., Nelson M.E., Granholm A.C. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 2003, 139:47-57.
30. Bittles A.H., Bower C., Hussain R., Glasson E.J. The four ages of Down syndrome. Eur. J. Public Health 2006, 17:221-225.
31. Bittles A.H., Glasson E.J. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev. Med. Child Neurol. 2004, 46:282-286.
32. Blackwood W., Corsellis J.A.N. Greenfeld's Neuropathology 1976, Yearbook Medical, Chicago.
33. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 1968, 114:797-811.
34. Brown J.H., Johnson M.H., Patterson S.J., Gilmore R., Longhi E., Karmiloff-Smith A. Spatial representation and attention in toddlers with Williams syndrome and Down syndrome. Neuropsychologia 2003, 41:1037-1046.
35. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378:776-779.
36. Caillé I., Allinquant B., Dupont E., Bouillot C., Langer A., Müller U., Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004, 131:2173-2181.
37. Caltagirone C., Nocentini U., Vicari S. Cognitive functions in adult Down's syndrome. Int. J. Neurosci. 1990, 54:221-230.
38. Carlesimo G.A., Marotta L., Vicari S. Long-term memory in mental retardation: evidence for a specific impairment in subjects with Down's syndrome. Neuropsychologia 1997, 35:71-79.
39. Casanova M.F., Walker L.C., Whitehouse P.J., Price D.L. Abnormalities of the nucleus basalis in Down's syndrome. Ann. Neurol. 1985, 18:310-313.
40. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., Carlson E.J., Staufenbiel M., Nixon R.A. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J. Neurosci. 2003, 23:6788-6792.
41. Chakrabarti L., Galdzicki Z., Haydar T.F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 2007, 27:11483-11495.
42. Chang K.T., Min K.T. Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat. Neurosci. 2005, 8:1577-1585.
43. Chang Q., Gold P.E. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiol. Learn. Mem. 2008, 89:167-177.
44. Chen Y., Dyakin V.V., Branch C.A., Ardekani B., Yang D., Guilfoyle D.N., Peterson J., Peterhoff C., Ginsberg S.D., Cataldo A.M., Nixon R.A. In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol. Aging 2008, 30:1453-1465.
45. Chen Y., Tang B.L. The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem. Biophys. Res. Commun. 2006, 341:1-5.
46. Cheng A., Haydar T.F., Yarowsky P.J., Krueger B.K. Concurrent generation of subplate and cortical plate neurons in developing trisomy 16 mouse cortex. Dev. Neurosci. 2004, 26:255-265.
47. Christianson A., Howson C.P., Modell B. March of Dimes Global Report on Birth Defects: The Hidden Toll of Dying and Disabled Children 2006, March of Dimes Birth Defects Foundation, White Plains, NY, p. 98.
48. Cipriani G., Bianchetti A., Trabucchi M. Donepezil use in the treatment of dementia associated with Down syndrome. Arch. Neurol. 2003, 60:292.
49. Clark D., Wilson G.N. Behavioral assessment of children with Down syndrome using the Reiss psychopathology scale. Am. J. Med. Genet. 2003, 118:210-216.
50. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
51. Colon E. The structure of cerebral cortex in Down syndrome. Neuropediatrie 1972, 3:362-376.
52. Contestabile A., Ciani E., Contestabile A. The place of choline acetyltransferase activity measurement in the " cholinergic hypothesis" of neurodegenerative diseases. Neurochem. Res. 2008, 33:318-327.
53. Contestabile A., Fila T., Bartesaghi R., Ciani E. Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain pathol. 2009, 19:224-237.
54. Contestabile A., Fila T., Bartesaghi R., Contestabile A., Ciani E. Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J. Neurochem. 2006, 97:515-526.
55. Contestabile A., Fila T., Cappellini A., Bartesaghi R., Ciani E. Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. Cell Prolif. 2009, 42:171-181.
56. Contestabile A., Fila T., Ceccarelli C., Bonasone P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
57. Conti L., Cattaneo E. Controlling neural stem cell division within the adult subventricular zone: an APPealing job. Trends Neurosci. 2005, 28:57-59.
58. Cooper J.D., Salehi A., Delcroix J.D., Howe C.L., Belichenko P.V., Chua-Couzens J., Kilbridge J.F., Carlson E.J., Epstein C.J., Mobley W.C. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10439-10444.
59. Coppus A., Evenhuis H., Verberne G.J., Visser F., van Gool P., Eikelenboom P., van Duijin C. Dementia and mortality in persons with Down's syndrome. J. Intellect. Disabil. Res. 2006, 50:768-777.
60. Corsi P., Coyle J.T. Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1793-1797.
61. Costa A.C., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 2005, 382:317-322.
62. Costa A.C., Walsh K., Davisson M.T. Motor dysfunction in a mouse model for Down syndrome. Physiol. Behav. 1999, 68:211-220.
63. Costa C.S.A., Scott-McKean J.J., Stasko M.R. Acute Injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2007, 33:1624-1632.
64. Coyle J.T., Oster-Granite M.L., Reeves R., Hohmann C., Corsi P., Gearhart J. Down syndrome and the trisomy 16 mouse: impact of gene imbalance on brain development and aging. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1991, 69:85-99.
65. Coyle J.T., Oster-Granite M.L., Reeves R.H., Gearhart J. Down syndrome. Alzheimer's disease and thetrisomy 16 mouse. Trends Neurosci. 1988, 11:390-394.
66. Crawford D.R., Leahy K.P., Abramova N., Lan L., Wang Y., Davies K.J. Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress. Arch. Biochem. Biophys. 1997, 342:6-12.
67. Crome L., Cowie V., Slater E. A statistical note on cerebellar and brain stem weight in Mongolism. J. Ment. Defic. Res. 1966, 10:69-72.
68. Dalton A.J., Crapper-McLachlan D.R. Clinical expression of Alzheimer's disease in Down's syndrome. Psychiatr. Clin. North Am. 1986, 9:659-670.
69. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.P., Artymyshyn R.P., Gardier A.M., Gerald C., Antonijevic I.A., Leonardo E.D., Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62:479-493.
70. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
71. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res. 1990, 360:263-280.
72. de Haan J.B., Cristiano F., Iannello R., Bladier C., Kelner M.J., Kola I. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum. Mol. Genet. 1996, 5:283-292.
73. Deb S., Hare M., Prior L. Symptoms of dementia among adults with Down's syndrome: a qualitative study. J. Intellect. Disabil. Res. 2007, 51:726-739.
74. Delabar J.M., Aflalo-Rattenbach R., Créau N. Developmental defects in Trisomy 21 and mouse models. Sci.World J. 2006, 1:1945-1964.
75. Delabar J.M., Theophile D., Rahmani Z., Chettouh Z., Blouin J.L., Prieur M., Noel B., Sinet P.M. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet. 1993, 1:114-124.
76. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav. Brain Res. 1996, 82:85-92.
77. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav. Brain Res. 1998, 90:199-201.
78. Devenny D.A., Krinsky-McHale S.G., Sersen G., Silverman W.P. Sequence of cognitive decline in dementia in adults with Down's syndrome. J. Intellect. Disabil. Res. 2000, 44:654-665.
79. Devenny D.A., Silverman V.P., Hill A.L., Jenkins E., Sersen E.A., Wisniewski K.E. Normal ageing in adults with Down's syndrome: a longitudinal study. J. Intellect. Disabil. Res. 1996, 40:208-221.
80. Devenny D.A., Wegiel J., Schupf N., Jenkins E., Zigman W., Krinsky-McHale S.J., Silverman W.P. Dementia of the Alzheimer's type and accelerated aging in down syndrome. Sci. Aging Knowl. Environ. 2005, 2005:dn1.
81. Dierssen M., Benavides-Piccione R., Martinez-Cue C., Estivill X., Florez J., Elston G.N., DeFelipe J. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb. Cortex 2003, 13:758-764.
82. Down J.L.H. Observations on an ethnic classification of idiots. Clin. Lect. Reports, London Hospital 1866, 3:259-262.
83. Dunst C.J. Sensorimotor development of infants with Down syndrome. Children with Down Syndrome 1990, 180-230. Cambridge University Press, New York. D. Cicchetti, M. Beeghly (Eds.).
84. Ellis N.R., Woodley-Zanthos P., Dulaney C.L. Memory for spatial location in children, adults, and mentally retarded persons. Am. J. Ment. Retard. 1989, 93:521-526.
85. Engidawork E., Lubec G. Molecular changes in fetal Down syndrome brain. J. Neurochem. 2003, 84:895-904.
86. Epstein C.J., Cox D.R., Epstein L.B. Mouse trisomy 16: an animal model of human trisomy 21 (Down syndrome). Ann. N. Y. Acad. Sci. 1985, 450:157-168.
87. Ermak G., Cheadle C., Becker K.G., Harris C.D., Davies K.J. DSCR1(Adapt78) modulates expression of SOD1. Faseb J. 2004, 18:62-69.
88. Ermak G., Davies K.J. DSCR1(Adapt78)-a Janus gene providing stress protection but causing Alzheimer's disease?. IUBMB Life 2003, 55:29-31.
89. Ermak G., Harris C.D., Davies K.J. The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress. FASEB J. 2002, 16:814-824.
90. Ermak G., Morgan T.E., Davies K.J. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J. Biol. Chem. 2001, 276:38787-38794.
91. Escorihuela R.M., Fernandez-Teruel A., Vallina I.F., Baamonde C., Lumbreras M.A., Dierssen M., Tobena A., Florez J. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 1995, 199:143-146.
92. Escorihuela R.M., Vallina I.F., Martinez-Cue C., Baamonde C., Dierssen M., Tobena A., Florez J., Fernandez-Teruel A. Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 1998, 247:171-174.
93. Esposito G., Imitola J., Lu J., De Filippis D., Scuderi C., Ganesh V.S., Folkerth R., Hecht J., Shin S., Iuvone T., Chesnut J., Steardo L., Sheen V. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum. Mol. Genet. 2008, 17:440-457.
94. Fernandez F., Garner C.C. Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behav. Brain Res. 2008, 188:233-237.
95. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., Garner C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
96. Ferrer I., Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in hippocampus. Acta Neuropathol. 1990, 79:680-685.
97. Fiedler J.L., Epstein C.J., Rapoport S.I., Caviedes R., Caviedes P. Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res. 1994, 658:27-32.
98. Fischer D.F., van Dijk R., Sluijs J.A., Nair S.M., Racchi M., Levelt C.N., van Leeuwen F.W., Hol E.M. Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP. Faseb J. 2005, 19:1451-1458.
99. Fleming L.M., Johnson G.V. Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP. Biochem. J. 1995, 309:41-47.
100. Folin M., Baiguera S., Conconi M.T., Pati T., Grandi C., Parnigotto P.P., Nussdorfer G.G. The impact of risk factors of Alzheimer's disease in the Down syndrome. Int. J. Mol. Med. 2003, 11:267-270.
101. Fotaki V., Dierssen M., Alcántara S., Martínez S., Martí E., Casas C., Visam J., Soriano E., Estivill X., Arbonés M.L. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 2002, 22:6636-6647.
102. Fowler A.E., Gelman R., Gleitman L.R. The course of lamguage learning in children with Down syndrome: Longitudinal and language level comparisons with young normally developing children. Constraints of Language Acquisition 1994, 91-140. Erlbaum, Hillsdale, NJ. H. Tager-Flusberg (Ed.).
103. Fuentes J.J., Genesca L., Kingsbury T.J., Cunningham K.W., Pérez-Riba M., Estivill X., de la Luna S. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet. 2000, 9:1681-1690.
104. Galante M., Jani H., Vanes L., Daniel H., Fisher E.M.C., Tybulewicz V.L.J., Bliss T.V.P., Morice E. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 2009, 18:1449-1463.
105. Galdzicki Z., Siarey R.J. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav. 2003, 2:167-178.
106. Gardiner K. Predicting pathway perturbations in Down syndrome. J. Neural. Transm. Suppl. 2003, 21-37.
107. Gardiner K., Fortna A., Bechtel L., Davisson M.T. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003, 318:137-147.
108. Gasparini L., Dityatev A. Beta-amyloid and glutamate receptors. Exp. Neurol. 2008, 212:1-4.
109. Gasparini L., Spillantini M.G. Molecular neuropathology in familial and sporadic frontotemporal dementia. Frontotemporal Dementia Syndromes 2007, Cambridge University Press, Cambridge. H. J.R. (Ed.).
110. Giaccone G., Tagliavini F., Linoli G., Bouras C., Frigerio L., Frangione B., Bugiani O. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci. Lett. 1989, 97.
111. Glasson E.J., Sullivan S.G., Hussain R., Petterson B.A., Montgomery P.D., Bittles A.H. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin. Gen. 2002, 62:390-393.
112. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122:1131-1135.
113. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
114. Godridge H., Reynolds G.P., Czudek C., Calcutt N.A., Benton M. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J. Neurol. Neurosurg. Psychiatry 1987, 50:775-778.
115. Golden J.A., Hyman B.T. Development of the superior temporal neocortex is anomalous in trisomy 21. J. Neuropathol. Exp. Neurol. 1994, 53:513-520.
116. Goldowitz D., Hamre K. The cells and molecules that make a cerebellum. Trends Neurosci. 1998, 21:375-382.
117. Gong C.X., Shaikh S., Grundke-Iqbal I., Iqbal K. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Brain Res. 1996, 741:95-102.
118. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
119. Govoni S., Bergamaschi S., Gasparini L., Quaglia C., Racchi M., Cattaneo E., Binetti G., Bianchetti A., Giovetti F., Battaini F., Trabuechi M. Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation. Neurology 1996, 47:1069-1075.
120. Granholm A.C., Ford K.A., Hyde L.A., Bimonte H.A., Hunter C.L., Nelson M., Albeck D., Sanders L.A., Mufson E.J., Crnic L.S. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol. Behav. 2002, 77:371-385.
121. Granholm A.C., Sanders L.A., Crnic L.S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 2000, 161:647-663.
122. Gregory C.A., Hodges J.R. Clinical features of frontal lobe dementia in comparison to Alzheimer's disease. J. Neural Transm. Suppl. 1996, 47:103-123.
123. Guidi S., Bonasoni P., Caccarelli C., Santini D., Gualtieri F., Ciani E., Bartesaghi R. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Phatol. 2008, 18:180-197.
124. Guihard-Costa A.M., Khung S., Delbecque K., Menez F., Delezoide A.L. Biometry of Face and Brain in Fetuses With Trisomy 21. Pediatr. Res. 2006, 59:33-38.
125. Gulesserian T., Seidl R., Hardmeier R., Cairns N., Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J. Investig. Med. 2001, 49:41-46.
126. Gyure K.A., Durham R., Stewart W.F., Smialek J.E., Troncoso J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 2001, 125:489-492.
127. Hall B. Delayed ontogenesis in human trisomy syndromes. Hereditas 1965, 52:334-344.
128. Hammerle B., Carnicero A., Elizalde C., Ceron J., Martinez S., Tejedor F.J. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation. Eur. J. Neurosci. 2003, 17:2277-2286.
129. Hammerle B., Vera-Samper E., Speicher S., Arencibia R., Martínez S., Tejedor F.J. Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in neural progenitor cells at the transition to neurogenic divisions. Dev. Biol. 2002, 246:259-273.
130. Hanson J.E., Blank M., Valenzuela R.A., Garner C.C., Madison D.V. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J. Physiol. 2007, 579:53-67.
131. Harris C.D., Ermak G., Davies K.J. Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product Calcipressin 1 (or RCAN1) in disease. Cell Mol. Life Sci. 2005, 62:2477-2486.
132. Hassold T., Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat. Rev. Genet. 2001, 2:280-291.
133. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., Toyoda A., Ishii K., Totoki Y., Choi D.K., Soeda E., Ohki M., Takagi T., Sakaki Y., Taudienk S., Blechschmidtk K., Polleyk A., Menzelk U., Delabar J., Kumpfk K., Lehmannk R., Patterson D., Reichwaldk K., Rumpk A., Schillhabelk M., Schudyk A., Zimmermannk W., Rosenthalk A., KudohI J., Shibuya K., KawasakiI K., AsakawaI S., ShintaniI A., SasakiI T., NagamineI K., MitsuyamaI S., Antonarakis S.E., MinoshimaI S., ShimizuI N., Nordsiek G., Hornischer K., Brandt P., Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Blöcker H., Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E., Haaf T., Wehrmeyer S., Borzym K., Gardiner K., Nizetickk D., Francis F., Lehrach H., Reinhardt R., Yaspo M.L. The DNA sequence of human chromosome 21. Nature 2000, 405:311-319.
134. Haydar T.F., Blue M.E., Molliver M.E., Krueger B.K., Yarowsky P.J. Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. J. Neurosci. 1996, 16:6175-6182.
135. Haydar T.F., Nowakowski R.S., Yarowsky P.J., Krueger B.K. Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. J. Neurosci. 2000, 20:4156-4164.
136. Heller J.H., Spiridigliozzi G.A., Sullivan J.A., Doraiswamy P.M., Krishnan R.R., Kishnani P.S. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am. J. Med. Genet. A 2003, 116A:111-116.
137. Hemingway-Eltomey J.M., Lerner A.J. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am. J. Psychiatry 1999, 159:1470.
138. Hof P.R., Bouras C., Perl D.P., Sparks D.L., Mehta N., Morrison J.H. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch. Neurol. 1995, 52:379-391.
139. Holland A.J., Hon J., Huppert F.A., Stevens F. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J. Intellect. Disabil. Res. 2000, 44:138-146.
140. Holland A.J., Hon J., Huppert F.A., Stevens F., Watson P. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br. J. Psychiatry 1998, 172.
141. Holtzman D.M., Santucci D., Kilbridge J., Chua-Couzens J., Fontana D.J., Daniels S.E., Johnson R.M., Chen K., Sun Y., Carlson E., Alleva E., Epstein C.J., Mobley W.C. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13333-13338.
142. Hsu L.Y. Genetic Disorders and the Fetus 1998, 179-248. Johns Hopkins Univ. Press, Baltimore. A. Milunsky (Ed.).
143. Huang W., Galdzicki Z., van Gelderen P., Balbo A., Chikhale E.G., Schapiro M.B., Rapoport S.I. Brain myo-inositol level is elevated in Ts65Dn mouse and reduced after lithium treatment. Neuroreport 2000, 11:445-448.
144. Hulme C., MacKenzie S. Working Memory and Severe Learning Difficulties 1992, Erlbaum, Hove, UK.
145. Hunter C.L., Bachman D., Granholm A.C. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann. Neurol. 2004, 56:675-688.
146. Hunter C.L., Bimonte-Nelson H.A., Nelson M., EcKman C.B., Granholm A.C. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol. Aging. 2004, 25:873-884.
147. Hunter C.L., Bimonte H.A., Granholm A.C. Behavioral comparison of 4 and 6-month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav. Brain Res. 2003, 138:121-131.
148. Hyde L.A., Crnic L.S. Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer's disease. Behav. Neurosci. 2001, 115:1239-1246.
149. Hyde L.A., Frisone D.F., Crnic L.S. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav. Brain Res. 2001, 118:53-60.
150. Insausti A.M., Megias M., Crespo D., Cruz-Orive L.M., Dierssen M., Vallina I.F., Insausti R., Florez J. Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci. Lett. 1998, 253:175-178.
151. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., Inoue I., Takaki M., Ueda Y., Sago H., Epstein C.J., Yamakawa K. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 2009, DOI: 10. 1111/j. 1471-4159. 2009. 06294. x.
152. Ishihara K., Amano K., Takaki E., Shimohata A., Sago H., Epstein C.J., Yamakawa K. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb. Cortex 2009, 10.1093/cercor/bhp1176.
153. Jernigan T.L., Bellugi U., Sowell E., Doherty S., Hesselink J.R. Cerebral morphologic distinctions between Williams and Down syndromes. Arch. Neurol. 1993, 50:186-191.
154. Jovanovic S.V., Clements D., MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 1998, 25:1044-1048.
155. Kahlem P., Sultan M., Herwig R., Steinfath M., Balzereit D., Eppens B., Saran N.G., Pletcher M.T., South S.T., Stetten G., Lehrach H., Reeves R.H., Yaspo M.L. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. Genome Res. 2004, 14:1258-1267.
156. Kasai H., Matsuzaki M., Noguchi J., Yasumatsu N., Nakahara H. Structure-stability function relationship of dendritic spines. Trends Neurosci. 2003, 26:360-368.
157. Kates W.R., Folley B.S., Lanham D.C., Capone G.T., Kaufmann W.E. Cerebral growth in Fragile X syndrome: review and comparison with Down syndrome. Microsc. Res. Tech. 2002, 57:159-167.
158. Kemper T.L. Down syndrome. In Cerebral Cortex 1991, 511-526. Plenum Press. A. Peters, E.J. Jones (Eds.).
159. Kesslak J.P., Nagata S.F., Lott I., Nalciouglu O. Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down's syndrome. Neurology 1994, 44:1039-1045.
160. Kida E., Wisniewski K.E., Wisniewski H.M. Early amyloid-fl deposits show different immunoreactivity to the amino- and carboxy-terminal regions of fl-peptide in Alzheimer' s disease and Down's syndrome brain. Neurosci. Lett. 1995, 193:105-108.
161. Kim H.S., Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 2009, 196:168-179.
162. Kingsbury T.J., Cunningham K.W. A conserved family of calcineurin regulators. Genes Dev. 2000, 14:1595-1604.
163. Kish S., Karlinsky H., Becker L., Gilbert J., Rebbetoy M., Chang L.J., DiStefano L., Hornykiewicz O. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J. Neurochem. 1989, 52:1183-1187.
164. Kishnani P.S., Sullivan J.A., Walter B.K., Spiridigliozzi G.A., Doraiswamy P.M., Krishnan K.R. Cholinergic therapy for Down's syndrome. Lancet 1999, 353:1064-1065.
165. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160.
166. Kola I., Hertzog P.J. Down syndrome and mouse models. Curr. Opin. Genet. Dev. 1998, 8:316-321.
167. Korenberg J.R., Chen X.N., Schipper R., Sun Z., Gonsky R., Gerwehr S., Carpenterc N., Daumer C., Dignan P., Disteche C., Graham J.M., Hugdins L., McGillivray B., Miyazaki K., Ogasawara N., Park J.P., Pagon R., Pueschel S., Sack G., Say B., Schuffenhauer S., Soukup S., Yamanaka T. Down syndrome phenotypes: The consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:4997-5001.
168. Krasuski J.S., Alexander G.E., Horwitz B., rapoport S.I., Schapiro M.B. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. Am. J. Psychiatry 2002, 159:74-81.
169. Krinsky-McHale S.J., Devenny D.A., Kittler P., Silverman W. Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer's disease in adults with Down syndrome. Am. J. Ment. Retard. 2008, 113:369-386.
170. Krinsky-McHale S.J., Devenny D.A., Silverman W.P. Changes in explicit memory associated with early dementia in adults with Down's syndrome. J. Intellect. Disabil. Res. 2002, 46:198-208.
171. Krupp J.J., Vissel B., Thomas C.G., Heinemann S.F., Westbrook G.L. Calcineurin acts via the C-terminus of NR2A to modulate desensitization of NMDA receptors. Neuropharmacology 2002, 42:593-602.
172. Kurt A.M., Kafa I.M., Dierssen M., Davies C.D. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res. 2004, 1022:101-109.
173. Kurt M.A., Davies D.C., Kidd M., Dierssen M., Florez J. Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res. 2000, 858:191-197.
174. Laffaire J., Rivals I., Dauphinot L., Pasteau F., Wehrle R., Larrat B., Vitalis T., Moldrich R.X., Rossier J., Sinkus R., Herault Y., Dusart I., Potier M.C. Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. BMC Genom. 2009, 10:138. doi:110.1186/1471-2164-1110-1138.
175. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6448-6453.
176. Lanfranchi S., Cornoldi C., Vianello R. Verbal and visuospatial working memory deficits in children with Down syndrome. Am. J. Mental Reterd. 2004, 109:456-466.
177. Larsen K.B., Laursen H., Græmb N., Samuelsena G.B., Bogdanovicc N., Pakkenberga B. Reduced cell number in the neocortical part of the human fetal brain in Down syndrome. Ann. Anatomy 2008, 190:421-427.
178. Laws G. Working memory in children and adolescents with Down syndrome: evidence from a colour memory experiment. J. Child Psychol. Psychiatry 2002, 43:353-364.
179. Lee V.M., Trojanowski J.Q. The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 1992, 2:653-656.
180. Lejeune J., Gautier M., Turpin R. Etude des chromosomes somatiques de neuf enfants mongoliens. Comptes Rendus. Hebd. Seances Acad. Sci. 1959, 248:1721-1722.
181. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 1996, 3:16-32.
182. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
183. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
184. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
185. Li Z., Yu T., Morishima M., Pao A., LaDuca J., Conroy J., Nowak N., Matsui S.I., Shiraishi I., Yu E.Y. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum. Mol. Genet. 2007, 16:1359-1366.
186. Lieberman D.N., Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994, 369:235-239.
187. Lin H.Y., Michtalik H.J., Zhang S., Andersen T.T., Van Riper D.A., Davies K.K., Ermak G., Petti L.M., Nachod S., Narayan A.V., Bhatt N., Crawford D.R. Oxidative and calcium stress regulate DSCR1 (Adapt78/MCIP1) protein. Free Radic. Biol. Med. 2003, 35:528-539.
188. Liu F., Liang Z., Wegiel J., Hwang Y., Iqbal K., Grundke-Iqbal I., Ramakrishna N., Gong C. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. Faseb J. 2008, 22:3224-3233.
189. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J.Q., Lee V.M. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Acta Neuropathol. 2006, 112.
190. Lobaugh N.J., Karaskov V., Rombough V., Rovet J., Bryson S., Greenbaum R., Haslam R.H., Koren G. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch. Pediatr. Adolesc. Med. 2001, 155:442-448.
191. Lockrow J., Prakasam A., Huang P., Bimonte-Nelson H., Sambamurti K., Granholm A.C. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp. Neurol. 2009, 216:278-289.
192. Lorenzi H.A., Reeves R.H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res. 2006, 1104:153-159.
193. Lott I.T., Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:172-178.
194. Lott I.T., Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging 2005, 26:383-389.
195. Lott I.T., Osann K., Doran E., Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch. Neurol. 2002, 59:1133-1136.
196. Lubec B., Yoo B.C., Dierssen M., Balic N., Lubec G. Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation. J. Neural. Transm. Suppl. 2001, 61:303-310.
197. Luo J., Ma J., Yu D.Y., Bu F., Zhang W., Tu L.H., Wei Q. Infusion of FK506, a specific inhibitor of calcineurin, induces potent tau hyperphosphorylation in mouse brain. Brain Res. Bull. 2008, 76:464-468.
198. Mann D.M., Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 1989, 89:169-179.
199. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J. Ment. Defic. Res. 1985, 29:125-135.
200. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome: a Golgi study. J. Comp. Neurol. 1976, 16:63-81.
201. Martinez-Cue C., Baamonde C., Lumbreras M., Paz J., Davisson M.T., Schmidt C., Dierssen M., Florez J. Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 2002, 134:185-200.
202. Martinez-Cue C., Rueda N., Garcia E., Davisson M.T., Schmidt C., Florez J. Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 2005, 163:174-185.
203. Mittwoch U. Mongolism and sex: a common problem of cell proliferation?. J. Med. Genet. 1971, 9:92-95.
204. Miyabara S., Gropp A., Winking H. Trisomy 16 in the mouse fetus associated with generalized edema and cardiovascular and urinary tract anomalies. Teratology 1982, 25:369-380.
205. Mohan, M., Bennett, C., Carpenter, P. K., 2009. Memantine for dementia in people with Down syndrome. Cochrane Database Syst Rev 1, CD007657.
206. Moldrich R.X. A yeast model of Down syndrome. Int. J. Dev. Neurosci. 2007, 25:539-543.
207. Moldrich R.X., Dauphinot L., Laffaire J., Vitalis T., Hérault Y., Beart P.M., Rossier J., Vivien D., Gehrig C., Antonarakis S.E., Lyle R., Potier M.C. Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. J. Neurosci. Res. 2009, 10.1002/jnr.22131.
208. Moore C.S., Roper R.J. The power of comparative and developmental studies for mouse models of Down syndrome. Mamm. Genome 2007, 18:431-443.
209. Moran T.H., Capone G.T., Knipp S., Davisson M.T., Reeves R.H., Gearhart J.D. The effects of piracetam on cognitive performance in a mouse model of Down's syndrome. Physiol. Behav. 2002, 77:403-409.
210. Mori C., Spooner E.T., Wisniewski K.E., Wisniewski T.M., Yamaguch H., Saido T.C., Tolan D.R., Selkoe D.J., Lemere C.A. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002, 9:88-102.
211. Morice E., Andreae L.C., Cooke S.F., Vanes L., Fisher E.M., Tybulewicz V.L., Bliss T.V. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn. Mem. 2008, 15:492-500.
212. Morice E., Denis C., Giros B., Nosten-Bertrand M. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 2004, 20:120-126.
213. Motte J., Williams R.S. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 1989, 77:535-546.
214. Mufson E.J., Cochran E., Benzing W., Kordower J.H. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging. Alzheimer's disease and Down's syndrome. Dementia 1993, 4:237-250.
215. Nadel L. Down syndrome in cognitive neuroscience perspective. Neurodevelopmental Disorders 1999, 197-222. MIT Press, Cambridge, MA. H. Tager-Flusberg (Ed.).
216. Nadel L. Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav. 2003, 2:156-166.
217. Nelson L., Johnson J.K., Freedman M., Lott I., Groot J., Chang M., Milgram N.W., Head E. Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:443-453.
218. Newpher T.M., Ehlers M.D. Spine microdomains for postsynaptic signaling and plasticity. Trends Cell Biol. 2009, 19:218-227.
219. Nichols S., Jones W., Roman M.J., Wulfeck B., Delis D.C., Reilly J., Bellugi U. Mechanisms of verbal memory impairment in four neurodevelopmental disorders. Brain Lang. 2004, 88:180-189.
220. Nieuwenhuis-Mark R.E. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res. Dev. Disabil. 2009, 30:827-838.
221. Nikolaienko A., Nguyen C., Crine L.S., Cios K.J., Gardiner K. Human chromosome 21/Down syndrome gene function and pathway database. Gene 2005, 364:90-98.
222. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., Sesay A., Modino S., Vanes L., Hernandez D., Linehan J.M., Sharpe P.T., Brandner S., Bliss T.V., Henderson D.J., Nizetic D., Tybulewicz V.L., Fisher E.M. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
223. Oller K., Siebert J.M. Babbling in prelinguistic retarded children. Am. J. Ment. Retard. 1988, 92:369-375.
224. Olson L.E., Richtsmeier J.T., Leszl J., Reeves R.H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004, 306:687-690.
225. Olson L.E., Roper R.J., Baxter L.L., Carlson E.J., Epstein C.J., Reeves R.H. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 2004, 230:581-589.
226. Olson L.E., Roper R.J., Sengstaken C.L., Peterson E.A., Aquino V., Galdzicki Z., Siarey R., Pletnikov M., Moran T.H., Reeves R.H. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum. Mol. Genet. 2007, 16:774-782.
227. Pallardó F.V., Degan P., d'Ischia M., Kelly F.J., Zatterale A., Calzone R., Castello G., Fernandez-Delgado R., Dunster C., Lloret A., Manini P., Pisanti M.A., Vuttariello E., Pagano G. Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 2006, 7:211-220.
228. Pennington B.F., Moon J., Edgin J., Stedron J., Nadel L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003, 74:75-93.
229. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388. Group., A. s. D. C. S.
230. Pine S.S., Landing B.H., Shankle W.R. Reduced inferior olivary neuron number in Early Down syndrome. Pediatr. Pathol. Lab. Med. 1997, 17:537-545.
231. Pinter J.D., Brown W.E., Schmitt J.E., Capone G.T., Reiss A.L. Amygdala and hippocampal volumes in children with Down syndrome: a high resolution MRI study. Neurology 2001, 10:972-974.
232. Pinter J.D., Eliez S., Schmitt J.E., Capone G.T., Reiss A.L. Neuroanatomy of Down's syndrome: a high-resolution MRI study. Am. J. Psychiatry 2001, 158:1659-1665.
233. Prasher V.P., Huxley A., Haque M.S. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-pilot study. Int. J. Geriatr. Psychiatry 2002, 17:270-278. Group., D. s. A. S.
234. Pritchard M.A., Kola I. The " gene dosage effect" hypothesis versus the " amplified developmental instability" hypothesis in Down syndrome. J. Neural. Transm. Suppl. 1999, 57:293-303.
235. Purser H.R., Jarrold C. Impaired verbal short-term memory in Down syndrome reflects a capacity limitation rather than atypically rapid forgetting. J. Exp. Child Psychol. 2005, 91:1-23.
236. Rachidi M., Lopes C. Mental retardation in Down syndrome: From gene dosage imbalance to molecular and cellular mechanisms. Neurosci. Res. 2007, 59:349-369.
237. Rahmani Z., Blouin J.L., Creau-Goldberg N., Watkins P.C., Mattei J.F., Poissonnier M., Prieur M., Chetrouh Z., Nicole A., Aurias A., Sinet P.M., Delabar J.M. Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:5958-5962.
238. Rast M., Meltzoff A.N. Memory and representation in young children with Down syndrome. Exploring deferred imitation and object permanence. Dev. Psychopathol. 1995, 7:393-407.
239. Raz N., Torres I.J., Briggs S.D., Spencer W.D., Thornton A.E., Loken W.J., Gunning F.M., McQuain J.D., Driesen N.R., Acker J.D. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 1995, 45:356-366.
240. Reeves R.H. Down syndrome mouse models are looking up. Trends Mol. Med. 2006, 12:237-240.
241. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., Schmidt C., Bronson R.T., Davisson M.T. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
242. Reisberg B., Ferris S.H., Anand R., Mir P., Geibel V., De Leon M.J., Roberts E. Effects of naloxone in senile dementia: a double-blind trial. N. Engl. J. Med. 1983, 308:721-722.
243. Risser D., Lubec G., Cairns N., Herrera-Marschitz M. Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci. 1997, 60:1231-1237.
244. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
245. Rondal J.A. Exceptional cases of language development in mental retardation: The relative autonomy of language as a cognitive system. Constraints of Language Acquisition 1993, 155-174. Erlbaum, Hillsdale, NJ. H. Tager-Flusberg (Ed.).
246. Roper R.J., Baxter L.L., Saran N.G., Klinedinst D.K., Beachy P.A., Reeves R.H. Defective cerebellar response to mitogenic Hedgehog signaling in Down syndrome mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1452-1456.
247. Roper R.J., Reeves R.H. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006, 2:231-236.
248. Roper R.J., VanHorn J.F., Cain C.C., Reeves R.H. A neural crest deficit in Down syndrome mice is associated with deficient mitotic response to Sonic hedgehog. Mech. Dev. 2008, 126:212-219.
249. Ropper A.H., Williams R.S. Relationship between plaques, tangles, and dementia in Down syndrome. Neurology 1980, 30:639-644.
250. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerrière A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006, 38:24-26.
251. Rowe J., Lavender A., Turk V. Cognitive executive function in Down's syndrome. Br. J. Clin. Psychol. 2006, 45:5-17.
252. Rueda N., Florez J., Marti{dotless}nez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 2008, 433:22-27.
253. Rueda N., Florez J., Marti{dotless}nez-Cue C. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav. Brain Res. 2008, 188:355-367.
254. Rueda N., Mostany R., Pazos A., Florez J., Martinez-Cue C. Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci. Lett. 2005, 380:197-201.
255. Rumble B., Retallack R., Hillbach C. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med. 1989, 320:1446-1454.
256. Rycroft B.K., Gibb A.J. Inhibitory interactions of calcineurin (phosphatase 2B) and calmodulin on rat hippocampal NMDA receptors. Neuropharmacology 2004, 47:505-514.
257. Ryoo S., Jeong H.K., Radnaabazar C., Yoo J., Cho H., HLee H., Kim I., Cheon Y., Ahn Y.S., Chung S.H., Song W. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 2007, 282:34850-34857.
258. Sago H., Carlson E.J., Smith D.J., Kilbridge J., Rubin E.M., Mobley W.C., Epstein C.J., Huang T.T. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6256-6261.
259. Sago H., Carlson E.J., Smith D.J., Rubin E.M., Crnic L.S., Huang T.T., Epstein C.J. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr. Res. 2000, 48:606-613.
260. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., Takimoto-Kimura R., Kleschevnikov A.M., Sambamurti K., Chung P.P., Xia W., Villar A., Campbell W.A., Shapiro Kulnane L., Nixon R.A., Lamb B.T., Epstein C.J., Stokin G.B., Goldstein L.S.B., Mobley W.C. Increased APP expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
261. Salehi A., Delcroix J.D., Mobley W.C. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 2003, 26:73-80.
262. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 1997, 336:1216-1222.
263. Sarsoza F., Saing T., Kayed R., Dahlin R., Dick M., Broadwater-Hollifield C., Mobley S., Lott I., Doran E., Gillen D., Anderson-Bergman C., Cribbs D.H., Glabe C., Head E. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009, 10.1007/s00401-00009-00530-00403.
264. Schapiro B.L., Haxby J.V., Grady C.L. Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. Neurobiol. Aging 1992, 13:723-734.
265. Schmidt-Sidor B., Wisniewski K.E., Shepard T.H., Sersen E.A. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin. Neuropathol. 1990, 9:181-190.
266. Schneider C., Risser D., Kirkner L., Kitzmüller E., Cairns N., Prast H., et al. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci. Lett. 1997, 222:183-186.
267. Schuchmann S., Heinemann U. Diminished glutathione levels cause spontaneous and mitochondria-mediated cell death in neurons from trisomy 16 mice: a model of Down's syndrome. J. Neurochem. 2000, 74:1205-1214.
268. Schuchmann S., Heinemann U. Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. Free Radic. Biol. Med. 2000, 28:235-250.
269. Schulz E., Scholz B. Neurohistological findings in the parietal cortex of children with chromosome aberrations. J. Hirnforsch. 1992, 33:37-62.
270. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp. Neurol. 2005, 193:469-480.
271. Seregaza Z., Roubertoux P.L., Jamon M., Soumireu-Mourat B. Mouse models of cognitive disorders in trisomy 21: a review. Behav. Genet. 2006, 36:387-404.
272. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
273. Shapiro B.L. Down syndrome: a sistruption of homeostasis. Am. J. Med. Genet. 1983, 14:241-296.
274. Shim S.K., Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 2002, 324:209-212.
275. Shukkur E.A., Shimohata A., Akagi T., Yu W., Yamaguchi M., Murayama M., Chui D., Takeuchi T., Amano K., Subramhanya H., Hashikawa T., Sago H., Epstein C.J., Takashima A., Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 2006, 15:2752-2762.
276. Siarey R.J., Carlson E.J., Epstein C.J., Balbo A., Rapoport S.I., Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
277. Siarey R.J., Stoll J., Rapoport S.I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology 1997, 36:1549-1554.
278. Siarey R.J., Villar A.J., Epstein C.J., Galdzicki Z. Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 2005, 49:122-128.
279. Siddiqui A., Lacroix T., Stastko M.R., Scott-McKean J.J., Costa A.C.S., Gardiner K.J. Genes Brain and Behavior. 7. 2008, 810-820.
280. Sorra K.E., Harris K.M. Overview on the structure, composition, function, development and plasticity of hippocampal dendritic spines. Hippocampus 2000, 10:501-511.
281. Stasko M.R., Costa A.C.S. Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav. Brain Res. 2004, 154:1-17.
282. Steffens M.L., Oller K., Lynch M., Urbano R. Vocal development in infants with Down syndrome and infants who are developing normally. Am. J. Ment. Retard. 1992, 97:235-246.
283. Suetsugu M., Mehraein P. Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. Acta Neuropathol. (Berl.) 1980, 50:207-210.
284. Sylvester P.E. The hippocampus in Down's syndrome. J. Ment. Defic. Res. 1983, 27(Pt 3):227-236.
285. Tager-Flusberg H. Language development in atypical children. The Development of Language 1999, 311-348. UCL Press, London. M. Barret (Ed.).
286. Takashima S., Becker L.E., Armstrong D.L., Chan F. Abnormal neuronal development in the visual cortex of the human fetus and infant with down's syndrome. A quantitative and qualitative Golgi study. Brain Res. 1981, 225:1-21.
287. Takashima S., Ieshima A., Nakamura H., Becker L.E. Dendrites, dementia and the Down syndrome. Brain Dev. 1989, 11:131-133.
288. Takashima S., Iida K., Mito T., Arima M. Dendritic and histochemical development and ageing in patients with Down's syndrome. J. Intellect. Disabil. Res. 1994, 38(Pt 3):265-273.
289. Teipel S.J., Alexander G.E., Schapiro M.B., Möller H.J., Rapoport S.I., Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain 2004, 127:811-824.
290. Teipel S.J., Bayer W., Alexander G.E., Bokde A.L., Zebuhr Y., Teichberg D., Muller-Spahn F., Schapiro M.B., Moller H.J., Rapoport S.I., Hampel H. Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol. Aging 2003, 24:85-94.
291. Teipel S.J., Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav. Genet. 2006, 36:405-415.
292. Teipel S.J., Schapiro M.B., Alexander G.E., Krasuski J.S., Horwitz B., Hoehne C., Moller H.J., Rapoport S.I., Hampel H. Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am. J. Psychiatry 2003, 160:1870-1878.
293. Terry R.D., Davies P. Dementia of the Alzheimer type. Ann. Rev. Neurosci. 1980, 3:77-95.
294. Theuns J., Brouwers N., Engelborghs S., Sleegers K., Bogaerts V., Corsmit E., De Pooter T., van Duijn C.M., De Deyn P.P., Van Broeckhoven C. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am. J. Hum. Genet. 2006, 78:936-946.
295. Thordadottir E.T., Chapman R.S., Wagner L. Complex sentence production by adolescents with Down syndrome. Appl. Psychol. 2002, 23:163-183.
296. Toso L., Cameroni I., Roberson R., Abebe D., Bissell S., Spong C.Y. Prevention of developmental delays in a Down syndrome mouse model. Obstet. Gynecol. 2008, 112:1242-1251.
297. Townsend M., Shankar G.M., Mehta T., Walsh D.M., Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
298. Turner C.A., Presti M.F., Newman H.A., Bugenhagen P., Crnic L., Lewis M.H. Spontaneous stereotypy in an animal model of Down syndrome: Ts65Dn mice. Behav. Genet. 2001, 31:393-400.
299. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann. Neurol. 1985, 17:273-277.
300. Vicari S. Memory development and intellectual disabilities. Acta Paediatr. Suppl. 2004, 93:60-63. discussion 63-64.
301. Vicari S., Bellucci S., Carlesimo G.A. Implicit and explicit memory: a functional dissociation in persons with Down syndrome. Neuropsychologia 2000, 38:240-251.
302. Vicari S., Bellucci S., Carlesimo G.A. Visual and spatial long-term memory: differential pattern of impairments in Williams and Down syndromes. Dev. Med. Child Neurol. 2005, 47:305-311.
303. Villar A.J., Belichenko P.V., Gillespie A.M., Kozy H.M., Mobley W.C., Epstein C.J. Identification and characterization of a new Down syndrome model, Ts[Rb(12. 1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm. Genome 2005, 16:79-90.
304. Visser F.E., Aldenkamp A.P., van Huffelen A.C., Kuilman M., Overweg J., van Wijk J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am. J. Ment. Retard. 1997, 101:400-412.
305. Visu-Petra L., Benga O., Tincas I., Miclea M. Visual-spatial processing in children and adolescents with Down's syndrome: a computerized assessment of memory skills. J. Intellect. Disabil. Res. 2007, 51:942-952.
306. Vuksic M., Petanjek Z., Rasin M.R., Kostovic I. Perinatal growth of prefrontal layer III pyramids in Down syndrome. Pediatr. Neurol. 2002, 27:36-38.
307. Waller B.R., McQuinn T., Phelps A.L., Markwald R.R., Lo C.W., Thompson R.P., Wessels A. Conotruncal anomalies in the trisomy 16 mouse: an immunohistochemical analysis with emphasis on the involvement of the neural crest. Anat. Rec. 2000, 260:279-293.
308. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
309. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924:133-140.
310. Wang J.W., David D.J., Monckton J.E., Battaglia F., Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. 2008, 28:1374-1384.
311. Webb S., Anderson R.H., Brown N.A. Endocardial cushion development and heart loop architecture in the trisomy 16 mouse. Dev. Dyn. 1996, 206:301-309.
312. Webb S., Brown N.A., Anderson R.H. Cardiac morphology at late fetal stages in the mouse with trisomy 16: consequences for different formation of the atrioventricular junction when compared to humans with trisomy 21. Cardiovasc. Res. 1997, 34:515-524.
313. Whitehouse P., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Xxxx M.R., Xxxx D. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239.
314. Whittle N., Sartori S.B., Dierssen M., Lubec G., Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007, 120:1465-1471.
315. Wilcock G.K., Esiri M.M. Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci. 1982, 56:343-356.
316. Winter T.C., Ostrovsky A.A., Komarniski C.A., Uhrich S.B. Cerebellar and frontal lobe hypoplasia in fetuses with trisomy 21: usefulness as combined US markers. Radiology 2000, 214:533-538.
317. Wisniewski H.M., Silverman W., Wegiel J. Ageing. Alzheimer disease and mental retardation. J. Intellect. Disabil. Res. 1994, 38:233-239.
318. Wisniewski K.E. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am. J. Med. Genet. Suppl 1990, 7:274-281.
319. Wisniewski K.E., Bobinski M. Hypothalamic abnormalities in Down syndrome. Prog. Clin. Biol. Res. 1991, 373:153-167.
320. Wisniewski K.E., Dalton A.J., McLachlan C., Wen G.Y., Wisniewski H.M. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985, 35:957-961.
321. Wisniewski K.E., Kida E. Abnormal neurogenesis and synaptogenesis in Down syndrome. Dev. Brain. Dysfunct. 1994, 7:289-301.
322. Wisniewski K.E., Laure-Kamionowska M., Connell F., Wen G.Y. Neuronal density and synaptogenesis in the postnatal stage of brain maturation in Down syndrome. The Neurobiology of Down Syndrome 1986, 29-44. Raven Press, New York. C.J. Epstein (Ed.).
323. Wisniewski K.E., Laure-Kamionowska M., Wisniewski H.M. Evidence of arrest of neurogenesis and synaptogensis in brains of patients with Down's syndrome. N. Engl. J. Med. 1984, 311:1187-1188.
324. Wisniewski K.E., Schmidt-Sidor B. Postnatal delay of myelin formation in brains from Down syndrome infants and children. Clin. Neuropathol. 1989, 8:55-62.
325. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann. Neurol. 1985, 17:278-282.
326. Yamamoto H., Hasegawa M., Ono T., Xxxx K., Xxxx T., Ihara Y., Miyamoto E. Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. J Biochem (Tokyo) 1995, 118:1224-1231.
327. Yates C.M., Simpson J., Gordon A. Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci. Lett. 1986, 11:189-192.
328. Yates C.M., Simpson J., Gordon A., Maloney A.F., Allison Y., Ritchie I.M., Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 1983, 280:119-126.
329. Yu D.Y., Luo J., Bu F., Song G.J., Zhang L.Q., Wei Q. Inhibition of calcineurin by infusion of CsA causes hyperphosphorylation of tau and is accompanied by abnormal behavior in mice. J. Biol. Chem. 2006, 387:977-983.
330. Zhang L., Goldman J.E. Developmental fates and migratory pathways of dividing progenitors in the postnatal rat cerebellum. J. Comp. Neurol. 1996, 370:536-550.
331. Zhang L., Goldman J.E. Generation of cerebellar interneurons from dividing progenitors in white matter. Neuron 1996, 16:47-54.
332. Zigman W.B., Schupf N., Sersen E., Silverman W. Prevalence of dementia in adults with and without Down syndrome. Am. J. Ment. Retard. 1996, 100:403-412.